Efficacy and Clinical Trials: Clinical trials, notably the Semaglutide Treatment Effect in People with Obesity (STEP) trials, have illuminated Semaglutides significant impact on weight loss
For example, a patient who struggles with constant hunger may benefit most from a GLP-1 therapy, while someone who eats primarily in response to stress or emotion may respond better to a medication that targets neurological reward pathways
Its Phase 2 weight loss data (24.2% at 48 weeks) and mechanistic advantages in hepatic fat reduction through glucagon receptor activation suggest it could surpass semaglutide's efficacy if Phase 3 results confirm the Phase 2 findings
But with so many options, its natural to wonder: which one is right for you
As the CF population ages, however, age-related components are expected to become even more prevalent, including CF-related diabetes (CFRD) where rates are approaching 100% in individuals with common severe CFTR mutations 3